Why Eli Lilly Stock Was a Winner Today

Key Points There’s a chance that an investigational obesity drug late in its development stage could…

Why Eli Lilly Stock Trounced the Market on Tuesday

Key Points There’s nothing like a successful clinical trial of a high-potential medicine to blast a…

Eli Roth’s The Horror Section: Revolutionizing Film Investment with Web3

Alvin Lang Aug 05, 2025 03:10 Eli Roth launches The Horror Section,…

Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs

The FDA gave compounders a grace period to wind down their production of the drugs after…

Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron’s Promising Phase 3 Results

This article was written by Follow With a background as an RN and an MBA, I…

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO)

This article was written by Follow Terry Chrisomalis is a private investor in the Biotech sector…